'Acute myeloid leukemia: a comprehensive review and 2016 update'

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Acute myeloid leukemia (AML) is the most common acute leukemia in adults.
• It is characterized by chromosomal translocations and gene mutations affecting hematopoietic cells.
• AML is a heterogeneous disease with variable prognosis despite risk stratification.

Purpose of the Study:

• To review recent advances in the treatment of Acute Myeloid Leukemia.
• To highlight the impact of genetic mutations on AML prognosis and management.
• To address treatment challenges in elderly AML patients.

Main Methods:

• Review of current literature on AML treatment.
• Analysis of the role of genetic mutations (e.g., FLT3-ITD, NMP1, CEBPA) in AML.
• Discussion of standard and novel therapeutic approaches.

Main Results:

• Recurrent genetic mutations refine individual prognosis and guide management strategies.
• Standard therapy involves cytarabine and anthracyclines, with stem cell transplantation for eligible patients.
• Elderly patients face poor prognosis and often cannot tolerate intensive regimens.

Conclusions:

• Advances in understanding AML genetics are improving personalized treatment.
• Novel therapeutic strategies are needed, particularly for elderly and high-risk patients.
• Continued research is crucial for improving outcomes in Acute Myeloid Leukemia.